Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × lorlatinib × Clear all

Phase

Status

Completed 12 Recruiting 10 Active not recruiting 10 Terminated 6 Not yet recruiting 6 Unknown 5 Withdrawn 1 No longer available 1 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm Metastasis 1 Lung Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 128 Cisplatin 116 Radiotherapy 112 pembrolizumab 109 Paclitaxel 96 Carboplatin 96 Gemcitabine 94 Magnetic Resonance Spectroscopy 80 Nivolumab 75 Bevacizumab 74 Fluorouracil 73 Dexamethasone 73 Radiosurgery 66 Docetaxel 59 Rituximab 58 Leucovorin 56 Oxaliplatin 54 Capecitabine 54 Doxorubicin 52 Biopsy 52 fludarabine 49 durvalumab 44 Drug Therapy 44 Cytarabine 42 fludarabine phosphate 40 Pemetrexed 40 Etoposide 40 Radiation 36 Prednisone 36 atezolizumab 35

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05948462 2023-12-13

NSCLC

SCRI Development Innovations, LLC

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡